Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

This is written in the approval document.

Reimbursement

CDS

Citation

Ceritinib Monotherapy, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6917/340_Ceritinib_monotherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) v::ALK Non-Small Cell Lung Cancer Ceritinib